Table 2.
Analysis of antibody titre (immunogenicity population)
| ZyCoV-D (n=135) | Placebo (n=130) | |
|---|---|---|
| Day 0 | ||
| GMT (95% CI) | 7 (7·00–7·00) | 7 (7·00–7·00) |
| Day 56 | ||
| GMT (95% CI) | 407·58 (266·73–622·83) | 57·97 (36·10–93·07) |
| GMFR (95% CI) | 58·23 (38·10–88·98) | 8·28 (5·16–13·30) |
| Day 84 | ||
| GMT (95% CI) | 952·67 (707·94–1282·00) | 154·82 (91·25–262·70) |
| GMFR (95% CI) | 136·10 (101·13–183·14) | 22·12 (13·04–37·53) |
GMT=geometric mean titre. GMFR=geometric mean fold rise.